Episoder
-
Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the drug negotiation provisions in the Inflation Reduction Act. The industry has been waiting with bated breath to see these prices, as they give the first real indication of how impactful this unprecedented legislation will be for pharma’s bottom line.
But this latest release of information raises as many questions as it answers, and on today’s podcast host Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert, for a broad ranging discussion of some of the next steps and consequences – intended or otherwise – of this legislation.
They talk about the many challenges CMS is likely to face in operationalising these prices and how much of the savings is likely to find its way to patients when the dust settles. They also discuss the prices themselves, why they aren’t lower, and just how low they really are, contextually. Additionally, they discuss some of the downstream consequences still to come from the IRA, including possible effects on oncolytics and the generics market.
For the pharma industry, the IRA drug pricing negotiation provision is shaping up to be one of the most consequential political stories of the decade. Tune in for a lively and in-depth discussion of what those consequences might look like.
-
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpointing and showcasing repeatable use cases to shape the targeted use of next-generation artificial intelligence and machine learning (AI-ML) innovation, particularly in the form of GenAI.
In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Manny Belabe, senior VP of customer success at ArisGlobal, about the Council and the role it seeks to play in furthering the success of GenAI in life sciences R&D.
Discussing also ArisGlobal’s LifeSphere NavaX GenAI features and functionality, Belabe notes too that a platform-centric development approach, based on common modules, can be leveraged to reduce data redundancy and general maintenance of that data.
At the present moment, however, there is also the pressing concern of sustainability in all sectors, and Belabe addresses practical issues around cooling infrastructure and space requirements for these technologies, as well.
-
Mangler du episoder?
-
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Fiske, chief scientific officer of Mythic Therapeutics, about minimising side effects for patients and the notion of patient-centred science.
-
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jane Reed, director of life sciences at Linguamatics, an IQVIA company, to discuss some of the major barriers preventing researchers from accessing the data they need to advance drug discovery and development and address safety concerns – and just how AI technologies can assist.
-
With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharmaphorum podcast COO of Enthought Mike Connell discusses the growing skills gap in R&D in life sciences and the 80/20 rule with web editor Nicole Raleigh, as well as the need for correct education of people and machines, both.
-
Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ lives.
Farrell Simon, chief commercial officer at Trevi Therapeutics, joins web editor Nicole Raleigh on the pharmaphorum podcast to discuss prioritising patients in clinical and commercial development, with an especial focus on chronic cough.
There are currently no approved therapies in either the US or the UK for what is a highly disruptive affliction, accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems.
Also discussing Trevi’s own work in the field, in particular a potential treatment for idiopathic pulmonary fibrosis (IPF), the conversation explores how to work more closely and holistically with patients in clinical development. Integrating the patient voice is, as Simon says, critical in clinical trial design. After all, the patient is the utmost stakeholder.
-
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ethan Drower, co-founder and CEO of Cite Medical Solutions, a company providing full Clinical Evaluation Report (CER) services and industry literature review for European Union Medical Device Regulation (or EU MDR) processes.
-
One of the things that makes patient engagement for pharma companies so challenging is that it's not something that can be added to one step of a process and then checked off the list. Real patient engagement needs to be integrated into processes every step of the way.
In today's podcast, brought to you by Reverba, Reverba CEO Cheryl Lubbert joins host Jonah Comstock to walk through the steps of the product lifestyle and explore the role of the patient at each of those stages: from preclinical through commercialisation and beyond.
Lubbert discusses the relationship between patient engagement, patient activation, patient centricity, and patient co-creation. She gives a wealth of examples from her experience as a long-time leader in the pharma industry to give context to the many ways to incorporate patients and their feedback into product discovery, clinical trials, product development, launch, and post-launch.
Finally, at the end of the podcast Lubbert gets into a few other hot-button issues including diversity and representation, as well as AI and how it will affect patient engagement. Tune in for interesting and actionable tips about patient engagement in pharma.
-
In today’s podcast, web editor Nicole Raleigh speaks with Carolyn Ward, director of clinical strategy at Particle Health Inc, a data transformation platform for healthcare, enabling organisations across the care continuum to turn medical records into actionable insights.
-
In today’s podcast, web editor Nicole Raleigh welcomes Dr Catherine Beech, CEO of Exonate, for a discussion on retinal vascular disease and a potential eye drop treatment for diabetic retinopathy and diabetic macular oedema, instead of invasive injections into the eye.
-
When it comes to life sciences manufacturing, there's nothing quite so daunting as a tech transfer - moving a product from development to commercialisation, or to a new facility or CDMO, presents many obstacles that have to be well thought out and planned. Delivering a tech transfer on schedule that stays below budget is no easy feat, but with the right best practices it can be done.
In today's podcast, brought to you by Lannett CDMO, Grant Brock, VP of operations at Lannett CDMO, and Frantz Maignan, Lannett CDMO's director of validation and tech services, join host Jonah Comstock for a deep dive into what challenges companies can encounter when it comes to tech transfers and some standout strategies for avoiding and surmounting those challenges.
The discussion includes the importance of thorough preparation and experimentation, good communication, and flexibility, and Brock and Maignan offer a few tips for choosing a manufacturing partner that can handle the unexpected bumps in the road that can crop up.
Tune in for a practical guide to an important and oft-overlooked aspect of pharma manufacturing.
-
We've recently passed the midpoint of 2024, so it's a good time to check in on trends – in this case, trends in the clinical trial space.
In today's podcast, brought to you by Advanced Clinical, host Jonah Comstock is joined by Jason Casarella, EVP of business development and marketing at Advanced Clinical and Caroline Redecker, chief strategy officer at Advanced Clinical, to discuss some of the findings in their recently released clinical trends report.
One of the biggest trends in the report is the rise of clinical trial site networks, and Casarella and Redecker drill down on why that’s happening and what it means for investigators. They also discuss how patient recruitment is changing in light of both changing technology and infrastructures, and new expectations about representation and diversity.
The conversation also veers into biotech investment trends and how those impact clinical trials, as well as the rise of AI and the various use cases being found for it in clinical research. Tune in for a wide-ranging snapshot into the evolving world of clinical research.
-
In this latest pharmaphorum podcast, web editor Nicole Raleigh speaks with Michael Kyle, chief medical officer at Currax Pharmaceuticals – a company working to advance a greater understanding of how to effectively treat obesity – about perceptions and options beyond the bounds of GLP-1s, including evolution of hypertension treatments.
-
The field of muscle stem cell research has been tangibly developing over the decades and in today’s pharmaphorum podcast wed editor Nicole Raleigh speaks with Dr Michael Rudnicki, co-founder and CSO of Satellos Biosciences, a company dedicated to developing novel therapeutics based on this science for those who live with Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases.
-
In today’s pharmaphorum podcast, Orr Inbar, co-founder and CEO of QuantHealth, a Tel Aviv-based AI-powered clinical trial design company, discusses how advances in data and AI can help.
-
In a new episode of the pharmaphorum podcast - recorded back in March, during Women’s History Month - web editor Nicole Raleigh spoke with Johan van Hylckama Vlieg, co-founder and chief scientific officer of Freya Biosciences, a Series A-financed, clinical stage, microbial immunotherapy company in women’s health, discussing the role of the vaginal microbiome in fertility, before he was due to speak at the first-of-its-kind Microbes in Women’s Health Congress in Copenhagen.
-
Sustainability is all important for the planet and its people, and in today’s podcast web editor Nicole Raleigh speaks with Harriet Lewis, director of public affairs and communications at Chiesi UK & Ireland, about how partnerships between the NHS and pharma industry can support the journey to more sustainable practices, from R&D and drug reimbursement to medicines and recycling.
-
The microbiome is ever more frequently spoken about of late, and so the pharmaphorum podcast invited Leo Grady, founder and CEO of Jona, to speak about at-home personal microbiome profiling, uncovering the relationship between human health and the gut.
-
In a conversation held earlier in the year as the four-year anniversary of the pandemic approached, the pharmaphorum podcast had as guest Murray Aitken, executive director of the IQVIA Institute for Human Data Science, to discuss the state of global medicines and the future outlook when it comes to research and development, and usage and spending appetites.
-
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael R Carazo Salas, founder and CEO of CellVoyant, an AI-first biotechnology company spun out from the University of Bristol.
- Se mer